- Home
- GYRE vs NX Comparison
GYRE vs NX Comparison
Compare GYRE & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NX
- Stock Information
- Founded
- GYRE 2002
- NX 1927
- Country
- GYRE United States
- NX United States
- Employees
- GYRE N/A
- NX N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NX Metal Fabrications
- Sector
- GYRE Health Care
- NX Industrials
- Exchange
- GYRE Nasdaq
- NX Nasdaq
- Market Cap
- GYRE 897.1M
- NX 852.8M
- IPO Year
- GYRE N/A
- NX N/A
- Fundamental
- Price
- GYRE $7.71
- NX $20.78
- Analyst Decision
- GYRE Strong Buy
- NX Strong Buy
- Analyst Count
- GYRE 1
- NX 1
- Target Price
- GYRE $18.00
- NX $38.00
- AVG Volume (30 Days)
- GYRE 86.3K
- NX 346.7K
- Earning Date
- GYRE 08-11-2025
- NX 09-04-2025
- Dividend Yield
- GYRE N/A
- NX 1.54%
- EPS Growth
- GYRE N/A
- NX N/A
- EPS
- GYRE 0.02
- NX 0.39
- Revenue
- GYRE $102,189,000.00
- NX $1,625,028,000.00
- Revenue This Year
- GYRE $21.04
- NX $49.00
- Revenue Next Year
- GYRE $89.64
- NX $2.99
- P/E Ratio
- GYRE $454.38
- NX $52.76
- Revenue Growth
- GYRE N/A
- NX 47.66
- 52 Week Low
- GYRE $6.11
- NX $15.30
- 52 Week High
- GYRE $19.00
- NX $32.23
- Technical
- Relative Strength Index (RSI)
- GYRE 49.56
- NX 49.96
- Support Level
- GYRE $7.61
- NX $20.91
- Resistance Level
- GYRE $8.40
- NX $22.81
- Average True Range (ATR)
- GYRE 0.47
- NX 0.72
- MACD
- GYRE 0.01
- NX -0.07
- Stochastic Oscillator
- GYRE 34.29
- NX 18.27
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.